vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $9.2M, roughly 1.3× Foghorn Therapeutics Inc.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -234.3%, a 235.6% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -0.7%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 12.5%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
FHTX vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $12.5M |
| Net Profit | $-21.7M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -258.2% | 1.5% |
| Net Margin | -234.3% | 1.3% |
| Revenue YoY | 223.8% | -0.7% |
| Net Profit YoY | -11.1% | 129.2% |
| EPS (diluted) | $-0.35 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $12.5M | ||
| Q3 25 | $8.2M | $14.6M | ||
| Q2 25 | $7.6M | $20.4M | ||
| Q1 25 | $6.0M | $14.6M | ||
| Q4 24 | $2.9M | $12.6M | ||
| Q3 24 | $7.8M | $16.9M | ||
| Q2 24 | $6.9M | $13.0M | ||
| Q1 24 | $5.0M | $9.9M |
| Q4 25 | $-21.7M | $163.0K | ||
| Q3 25 | $-15.8M | $-1.1M | ||
| Q2 25 | $-17.9M | $2.7M | ||
| Q1 25 | $-18.8M | $80.0K | ||
| Q4 24 | $-19.5M | $-559.0K | ||
| Q3 24 | $-19.1M | $3.0M | ||
| Q2 24 | $-23.0M | $856.0K | ||
| Q1 24 | $-25.0M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | -258.2% | 1.5% | ||
| Q3 25 | -226.9% | -5.4% | ||
| Q2 25 | -279.2% | 9.4% | ||
| Q1 25 | -385.0% | 1.8% | ||
| Q4 24 | -840.5% | -1.8% | ||
| Q3 24 | -305.5% | 19.0% | ||
| Q2 24 | -386.6% | 8.0% | ||
| Q1 24 | -558.3% | 11.3% |
| Q4 25 | -234.3% | 1.3% | ||
| Q3 25 | -194.4% | -7.7% | ||
| Q2 25 | -237.3% | 13.1% | ||
| Q1 25 | -316.4% | 0.5% | ||
| Q4 24 | -682.9% | -4.4% | ||
| Q3 24 | -244.9% | 18.1% | ||
| Q2 24 | -333.6% | 6.6% | ||
| Q1 24 | -495.4% | 9.0% |
| Q4 25 | $-0.35 | $0.00 | ||
| Q3 25 | $-0.25 | $-0.02 | ||
| Q2 25 | $-0.28 | $0.04 | ||
| Q1 25 | $-0.30 | $0.00 | ||
| Q4 24 | $-0.23 | $0.00 | ||
| Q3 24 | $-0.31 | $0.04 | ||
| Q2 24 | $-0.45 | $0.01 | ||
| Q1 24 | $-0.59 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $17.6M |
| Total Assets | $198.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $1.3M | ||
| Q3 25 | $89.3M | $429.0K | ||
| Q2 25 | $72.6M | $4.1M | ||
| Q1 25 | $61.0M | $1.8M | ||
| Q4 24 | $55.5M | $1.4M | ||
| Q3 24 | $57.7M | $2.9M | ||
| Q2 24 | $138.9M | $2.4M | ||
| Q1 24 | $79.3M | $2.0M |
| Q4 25 | $-108.5M | $17.6M | ||
| Q3 25 | $-89.7M | $17.2M | ||
| Q2 25 | $-76.7M | $18.2M | ||
| Q1 25 | $-61.7M | $15.2M | ||
| Q4 24 | $-45.5M | $14.9M | ||
| Q3 24 | $-28.3M | $15.2M | ||
| Q2 24 | $-14.3M | $11.9M | ||
| Q1 24 | $-97.5M | $5.0M |
| Q4 25 | $198.1M | $50.1M | ||
| Q3 25 | $205.0M | $54.0M | ||
| Q2 25 | $226.2M | $60.0M | ||
| Q1 25 | $258.7M | $57.0M | ||
| Q4 24 | $284.0M | $50.0M | ||
| Q3 24 | $308.4M | $48.0M | ||
| Q2 24 | $328.6M | $40.8M | ||
| Q1 24 | $255.0M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $1.8M | ||
| Q3 25 | $-18.9M | $-2.5M | ||
| Q2 25 | $-21.0M | $-654.0K | ||
| Q1 25 | $-24.0M | $-7.2M | ||
| Q4 24 | $-24.5M | $2.2M | ||
| Q3 24 | $-21.0M | $4.2M | ||
| Q2 24 | $-25.5M | $-565.0K | ||
| Q1 24 | $-29.3M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | $-404.0K | ||
| Q3 24 | $-21.3M | $2.8M | ||
| Q2 24 | $-25.6M | $-1.0M | ||
| Q1 24 | $-29.4M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | -3.2% | ||
| Q3 24 | -273.0% | 16.6% | ||
| Q2 24 | -371.0% | -8.0% | ||
| Q1 24 | -583.1% | -39.9% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | 20.6% | ||
| Q3 24 | 4.0% | 8.3% | ||
| Q2 24 | 0.2% | 3.7% | ||
| Q1 24 | 2.0% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
